Literature DB >> 9215649

Inhibition of HIV infection of H9 cells by chlorpromazine derivatives.

I Hewlett1, S Lee, J Molnar, S Foldeak, P S Pine, J L Weaver, A Aszalos.   

Abstract

The binding between the HIV surface protein, gp120, and the CD4 coreceptor is known to be initiated by electrostatic interactions. Because of the ability of chlorpromazine to interact with proteins by charge transfer, we tested several derivatives for their ability to block binding of HIV to CD4+ cells. We have shown that 7,8-dioxo-chlorpromazine blocks binding of fluorescein isothiocyanate-labeled anti-Leu3a and rgp120 to peripheral human blood T4 cells and blocks syncytia formation between gp120- and CD4-expressing cells. We also found that 7,8-dioxo-chlorpromazine blocks HIV infectivity of H9 cells and acts synergistically with zidovudine.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9215649     DOI: 10.1097/00042560-199705010-00003

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr Hum Retrovirol        ISSN: 1077-9450


  4 in total

1.  A combination of low-dose chlorpromazine and neutralizing antibodies inhibits the spread of JC virus (JCV) in a tissue culture model: implications for prophylactic and therapeutic treatment of progressive multifocal leukencephalopathy.

Authors:  W J Atwood
Journal:  J Neurovirol       Date:  2001-08       Impact factor: 2.643

2.  Repurposing chlorpromazine to treat COVID-19: The reCoVery study.

Authors:  M Plaze; D Attali; A-C Petit; M Blatzer; E Simon-Loriere; F Vinckier; A Cachia; F Chrétien; R Gaillard
Journal:  Encephale       Date:  2020-05-16       Impact factor: 1.291

3.  [Repurposing of chlorpromazine in COVID-19 treatment: the reCoVery study].

Authors:  M Plaze; D Attali; A-C Petit; M Blatzer; E Simon-Loriere; F Vinckier; A Cachia; F Chrétien; R Gaillard
Journal:  Encephale       Date:  2020-04-29       Impact factor: 1.291

4.  Screened antipsychotic drugs inhibit SARS-CoV-2 binding with ACE2 in vitro.

Authors:  Jiayu Lu; Yajing Hou; Shuai Ge; Xiangjun Wang; Jue Wang; Tian Hu; Yuexin Lv; Huaizhen He; Cheng Wang
Journal:  Life Sci       Date:  2020-12-10       Impact factor: 6.780

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.